Literature DB >> 15209755

Diabetes control and complications: the role of glycated haemoglobin, 25 years on.

S L Jeffcoate1.   

Abstract

The long-term complications of diabetes have major consequences for individual subjects and growing healthcare delivery and cost implications for society. Evidence for the benefits of good glycaemic control, as monitored by glycated haemoglobin measurements, has been developed in the 25 years since they were introduced to the point where HbA(1c) assays play central roles in patient management, clinical guidance and audit, and clinical trial design. In this review this evidence is examined and three classes of uncertainty identified that diminish confidence in the effectiveness of these roles for HbA(1c). 1 Analytical variability between different methods for HbA(1c) has restricted the application of clinical targets and this problem has recently been addressed by reference method standardization. There are two approaches to this which result in different HbA(1c) values and this discrepancy needs to be resolved. 2 Biological variability in HbA(1c) values between individuals also restricts its predictive role when applied to populations. The correlations between HbA(1c) measurements and various components of glycaemia (overall, fasting, postprandial) are still uncertain and differences in protein glycation and de-glycation are greater between subjects than often thought. The influence of variability in erythrocyte life span is an area where research is needed, especially in diabetic subjects. 3 Clinical variability is the most important and complex area of uncertainty. A predictive link between HbA(1c) and clinical outcomes is not as clear-cut as often stated. The correlation with the development of microvascular disease is well established in Type 1 diabetes, but in Type 2 subjects (90% of those with diabetes) the evidence that HbA(1c) monitoring is of value in predicting or preventing macrovascular disease is not strong, although it is the major cause of morbidity and early death in this group. It is recommended that, as a matter of urgency, these issues be examined, particularly within the context of self-care in diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15209755     DOI: 10.1046/j.1464-5491.2003.01065.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  57 in total

1.  Basic performance of an enzymatic method for glycated albumin and reference range determination.

Authors:  Takuji Kohzuma; Tamotsu Yamamoto; Yumiko Uematsu; Zak K Shihabi; Barry I Freedman
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

2.  Standardization of HbA1c: good or bad?

Authors:  Sally M Marshall
Journal:  Nat Rev Endocrinol       Date:  2010-05-04       Impact factor: 43.330

3.  Standardisation of glycated haemoglobin.

Authors:  Philip Home; Jean-Claude Mbanya; Ed Horton
Journal:  BMJ       Date:  2004-11-20

4.  How should HbA1c measurements be reported?

Authors:  F Gorus; C Mathieu; E Gerlo
Journal:  Diabetologia       Date:  2006-01       Impact factor: 10.122

5.  Characterization of alterations in diabetic myocardial tissue using high resolution MRI.

Authors:  Rajaprasad Loganathan; Mehmet Bilgen; Baraa Al-Hafez; Irina V Smirnova
Journal:  Int J Cardiovasc Imaging       Date:  2005-12-13       Impact factor: 2.357

6.  Haemoglobin A1c goal attainment in relation to dose in patients with diabetes mellitus taking metformin: a nested, case-control study.

Authors:  Fernie J A Penning-van Beest; Bruce H R Wolffenbuttel; Ron M C Herings
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Management of diabetes in dialysis patients.

Authors:  Mark E Williams
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

8.  Altered disease course after initiation of self-monitoring of blood glucose in noninsulin-treated type 2 diabetes (ROSSO 3).

Authors:  Hubert Kolb; Berthold Schneider; Lutz Heinemann; Volker Lodwig; Werner A Scherbaum; Stephan Martin
Journal:  J Diabetes Sci Technol       Date:  2007-07

9.  A review of glycated albumin as an intermediate glycation index for controlling diabetes.

Authors:  H Vernon Roohk; Asad R Zaidi
Journal:  J Diabetes Sci Technol       Date:  2008-11

10.  Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes.

Authors:  Masafumi Koga; Jun Murai; Hiroshi Saito; Soji Kasayama
Journal:  Diabetes Care       Date:  2009-10-21       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.